Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine

Journal of Controlled Release(2022)10.1016/j.jconrel.2022.05.023Source: DataRank Database

Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine is a research paper published in Journal of Controlled Release (2022). On theSindex it has a DataRank of 0. It has been cited 44 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access44 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 3.75)OA: greenTopics (57)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

M. Cole Keenum ORCID,Bhawana Pandey ORCID,Alexander Beach,Pallab Pradhan ORCID,Casey E. Vantucci ORCID

Live enrichment

PubMed:35577151 PMC:PMC9121740 OpenAlex:https://openalex.org/W4280538221

National Cancer Institute

Grant: P30CA138292

National Institute of Allergy and Infectious Diseases

Grant: U01-AI124270-02

National Science Foundation

Grant: T32-GM0843

NIGMS NIH HHS

Grant: T32 GM008433

NIAID NIH HHS

Grant: U01 AI124270

Children's Healthcare of Atlanta

Parker H. Petit Institute for Bioengineering and Bioscience

National Institutes of Health

Georgia Tech Foundation

Winship Cancer Institute

FWCI

3.75

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9121740

publisherhttps://api.elsevier.com/content/article/PII:S0168365922002851?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0168365922002851?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jconrel.2022.05.023

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesImmune Response and InflammationAdjuvants, ImmunologicAnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesDEAD Box Protein 58Drug Delivery SystemsImmunity, HumoralImmunoglobulin GMiceNanoparticlesReceptors, ImmunologicSARS-CoV-2Spike Glycoprotein, CoronavirusToll-Like Receptor 4

MeSH Terms

DEAD Box Protein 58COVID-19SARS-CoV-2COVID-19 VaccinesAdjuvants, ImmunologicAnimalsAntibodies, ViralImmunoglobulin GReceptors, ImmunologicDrug Delivery SystemsToll-Like Receptor 4MiceNanoparticlesImmunity, HumoralAntibodies, NeutralizingSpike Glycoprotein, Coronavirus

Keywords

Protein subunitSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Immune systemVirologyTLR4Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakVaccine adjuvantChemistryMedicinePharmacologyImmunologyBiochemistryGeneInternal medicineInfectious disease (medical specialty)Adaptive Immune ResponseMonophosphoryl Lipid ACombination AdjuvantSars-cov-2 Spike ProteinCovid-19 Protein Subunit VaccineIntranasal Versus Intramuscular Vaccination

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Inhalable hybrid nanovaccines with virus-biomimetic structure boost protective immune responses against SARS-CoV-2 variants

10.6084/m9.figshare.25302884.v1figshare

Additional file 1 of Inhalable hybrid nanovaccines with virus-biomimetic structure boost protective immune responses against SARS-CoV-2 variants

10.6084/m9.figshare.25302884figshare